About Quratis
Quratis is a company based in Seoul (South Korea) founded in 2016. Quratis offers products and services including QTP101, QTP104, CPP Platform, Peptide Nucleic Acid Complexes, and CMO&CDMO Services. Quratis operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
- Headquarter Seoul, South Korea
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website quratis.com/ko
- Legal Name Quratis Inc.
- Annual Revenue$1.7 M (USD)557.29as on Dec 31, 2025
- Net Profit-$20.54 M (USD)-12.97as on Dec 31, 2025
- EBITDA-$4.11 M (USD)61.03as on Dec 31, 2025
Associated legal entities of Quratis
Quratis operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of Quratis
Quratis offers a comprehensive portfolio of products and services, including QTP101, QTP104, CPP Platform, Peptide Nucleic Acid Complexes, and CMO&CDMO Services.
Tuberculosis vaccine combining antigens and immune enhancers.
COVID-19 mRNA vaccine for viral protection.
Platform for cell-penetrating peptides in drug transport.
Complexes for nucleic acid binding and therapeutic applications.
Custom services for biological product development and production.
Funding Insights of Quratis
- Total Rounds 1
All 1 funding rounds of Quratis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | – | Seed | – | – | – |
People of Quratis
1 people are tracked at Quratis (1 in leadership).
| Name | Role | Group |
|---|---|---|
Kwan-Goo Cho | CEO | Leadership |
Complete people profiles for Quratis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Quratis
Quratis is a publicly listed company on the KRX with ticker symbol 348080 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Jun 2023
- Listed onKRX: 348080
- Listed entityQuratis Inc.
- Exchange sectorHealth technology
- ISINKR7348080003
- Share price3,740.00 KRW (-4.96% on the day) · 2026-10-08
- Market capitalisation47,975,796,471.00 KRW
- EPS (diluted, trailing year)-2,866.58 KRW
- Volume (last session)36,507
Financials of Quratis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.46B KRW | -29.67B KRW | -5.93B KRW |
| 2024 | 373.8M KRW | -26.27B KRW | -15.22B KRW |
| 2023 | 1.03B KRW | -16.99B KRW | -12.11B KRW |
| 2022 | 8.41B KRW | -35.76B KRW | -16.29B KRW |
| 2021 | 1.59B KRW | -20.38B KRW | -14.00B KRW |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for Quratis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Quratis
3 dated milestones of Quratis across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Quratis is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
Competitors of Quratis
Quratis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| lodotherapeutics.com | 2015 | New York, United States | $19.87M | 24 | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | |
| symbiomix.com | 2012 | Newark, United States | $66.55M | – | Late-stage biopharma antibiotics for gynecological infections are developed. | |
| emergentbiosolutions.com | 1998 | Gaithersburg, United States | – | 1 | Vaccines for viral infections are developed by the company. | |
| spybiotech.com | 2017 | Oxford, United Kingdom | $38.6M | 10 | Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology | |
| elusys.com | 1999 | Montville, United States | $50M | 15 | Antibody therapeutics for anthrax and infectious diseases are developed. | |
| basilea.com | 1999 | Basel, Switzerland | – | – | Antibiotics, antifungals, and oncology drugs are developed for disease treatment. |
Detailed competitors of Quratis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Quratis
The website of Quratis (quratis.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▲ 58.2% vs previous month
Latest news on Quratis
Complete news archive for Quratis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Quratis
10 companies that operate in the same segment as Quratis (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Quratis
Quratis was founded in 2016 and raised its 1st funding round 7 years after it was founded.
Quratis is headquartered in Seoul, South Korea.
Kwan-Goo Cho is the current CEO of Quratis.
Annual revenue of Quratis is $1.7M as on Dec 31, 2025.
Quratis was founded in 2016 in Seoul, South Korea, within the biotechnology sector. Focus is placed on developing vaccines and cell therapies to address tuberculosis. The lead program involves the ID93 fusion protein paired with the GLA-SE adjuvant, which has completed Phase I clinical trials. This approach aims to strengthen immune responses generated by the BCG vaccine, supporting ongoing efforts in infectious disease treatment.
Quratis's top competitors include Insmed, Basilea and Eligo Bioscience.
Quratis offers QTP101, QTP104, CPP Platform, Peptide Nucleic Acid Complexes, and CMO&CDMO Services.
Yes, Quratis is publicly traded on KRX under the ticker symbol 348080.
Quratis operates through ,.